WuXi Biologics (Cayman) (WXXWY) Stock Price, News & Analysis

Company Overview

WuXi Biologics (Cayman) Inc. is a global contract research, development and manufacturing organization (CRDMO) focused on biologic medicines. The company works with pharmaceutical and biotechnology customers to support the development and production of biologic therapies, including monoclonal antibodies, recombinant proteins, vaccines and other complex biological products.

Its services span early-stage discovery and cell-line development through process development, clinical manufacturing, regulatory support and commercial-scale production. WuXi Biologics also provides capabilities for newer modalities, including certain bispecific antibodies, antibody-drug conjugates, gene therapies and cell therapies, helping customers advance programs from laboratory research to market supply.

The company was established in 2010 as part of WuXi AppTec and became a separately listed business in Hong Kong in 2018. WuXi Biologics serves pharmaceutical and biotechnology companies internationally through operations and facilities in China, the United States, Ireland, Germany and other locations. The company is led by Chief Executive Officer Dr. Chris Chen.

Key Stats

• Today's Range: $12.89 to $13.15
• 50-Day Range: $10.16 to $14.79
• 52-Week Range: $7.30 to $14.80
• Volume: 36,413 shs
• Average Volume: 70,696 shs
• Market Capitalization: $26.88 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

WuXi Biologics (Cayman) Stock Analysis - MarketRank™

WuXi Biologics (Cayman) scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

WuXi Biologics (Cayman) has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

WuXi Biologics (Cayman) has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 19.57%

Earnings Growth

Earnings for WuXi Biologics (Cayman) are expected to grow by 19.57% in the coming year, from $0.46 to $0.55 per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of WuXi Biologics (Cayman) has been sold short.

Short Interest Ratio / Days to Cover

WuXi Biologics (Cayman) has a short interest ratio ("days to cover") of 0.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in WuXi Biologics (Cayman) has recently increased by 71.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

WuXi Biologics (Cayman) does not currently pay a dividend.

Dividend Growth

WuXi Biologics (Cayman) does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: N/A

News Sentiment

WuXi Biologics (Cayman) has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for WuXi Biologics (Cayman) this week, compared to 1 article on an average week.

Search Interest

2 people have searched for WXXWY on MarketBeat in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, WuXi Biologics (Cayman) insiders have not sold or bought any company stock.

Percentage Held by Institutions

WuXi Biologics (Cayman) has minimal institutional ownership at this time.

Company Calendar

• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:WXXWY
• CIK: N/A
• Web: www.wuxibiologics.com
• Phone: 8651081831205
• Fax: N/A
• Employees: 13,252
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,058,170,000
• Free Float: N/A
• Market Cap: $26.88 billion
• Optionable: Not Optionable
• Beta: N/A